Evidence map›Paper›PMID 31037574›Full record

ArticleInflammopharmacology2019

Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.

Philipp Guenthoer, Kerstin Fuchs, Gerald Reischl, Leticia Quintanilla-Martinez, Irene Gonzalez-Menendez, Stefan Laufer, Bernd J Pichler, Manfred Kneilling

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Philipp GuenthoerDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Kerstin FuchsDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Gerald ReischlDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Leticia Quintanilla-MartinezDepartment of Pathology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Irene Gonzalez-MenendezDepartment of Pathology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Stefan LauferDepartment of Pharmaceutical and Medicinal Chemistry, University of Tuebingen, Tuebingen, Germany.
Bernd J PichlerDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
Manfred KneillingDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany. manfred.kneilling@med.uni-tuebingen.de.
University of Tübingen · DESiemens (Germany) · DESTZ eyetrial · DE

Funding

Deutsche Forschungsgemeinschaft CRC 156Deutsche Forschungsgemeinschaft Project C03
6 · The paper itself

Abstract

backgroundMitogen-activated protein kinase (MAPK) signaling plays an important role in inflammatory diseases such as rheumatoid arthritis (RA).The aim of our study was to elucidate the therapeutic potential of the highly selective p38 MAPK inhibitor Skepinone-L and the dual inhibitor LN 950 (p38 MAPK and JNK 3) in the K/BxN serum transfer model of RA. Additionally, we aimed to monitor MAPK treatment non-invasively in vivo using the hypoxia tracer [

methodsTo induce experimental arthritis, we injected glucose-6-phosphate isomerase autoantibody-containing serum in BALB/c mice. MAPK inhibitor or Sham treatment was administered per os once daily. On days 3 and 6 after arthritis induction, we conducted PET imaging with [

resultsSkepinone-L and LN 950 were applicable to suppress the severity of experimental arthritis confirmed by reduced ankle swelling and histopathological analysis. Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis. Hypoxia imaging with [

conclusionBoth the selective p38 MAPK inhibitor Skepinone-L and the dual (p38 MAPK and JNK 3) inhibitor LN 950 exhibited significant therapeutic effects during experimental arthritis. Thus, our study contributes to the ongoing discussion on the use of p38 MAPK as a potential target in RA.

Indexed as

AnimalsArthritis, ExperimentalDibenzocycloheptenesDisease Models, AnimalGlucose-6-Phosphate IsomeraseImidazolesMiceMice, Inbred BALB CMisonidazoleMitogen-Activated Protein Kinase 10p38 Mitogen-Activated Protein KinasesPositron-Emission TomographyProtein Kinase InhibitorsPyridinesDibenzocycloheptenesfluoromisonidazoleGlucose-6-Phosphate IsomeraseImidazolesLN950MisonidazoleMitogen-Activated Protein Kinase 10p38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsPyridinesskepinone-LHypoxia imagingMitogen-activated protein kinasePETRheumatoid arthritis

Identifiers

PMID31037574
OpenAlexW2943355117

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.